Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Severe intracranial atherosclerosis with concomitant stenosis is responsible for
approximately 10% of all strokes. Retrospective studies have indicated that up to 50% of
patients with a recently symptomatic intracranial stenosis experience recurrent ischemic
events. Due to the high stroke risk, patients with high grade 70% symptomatic intracranial
stenosis represent the main target group for endovascular treatment. Atorvastatin is widely
used in the treatment of hyperlipidemia, especially after acute myocardial infarction.
High-dose atorvastatin has been known to stop the progression of atherosclerosis and to
decrease the levels of inflammatory markers. Several recent clinical trials have proved
atorvastatin can reduce restenosis after stent implantation in coronary artery. But the
feasibility of atorvastatin in preventing restenosis in patients with intracranial stenting
has not been evaluated.The purpose of this prospective, randomized, single-blinded trial is
to evaluate the effect of atorvastatin 80 mg daily in preventing restenosis and related
vascular events in patients with intracranial stent implantation.